Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adults
Objectives: This phase III placebo-controlled study evaluated the immunogenicity and safety of MenACWY-CRM vaccination in healthy Korean adolescents and adults. Methods: Serum bactericidal activity with human complement (hSBA) was measured before and 1 month after vaccination against all four menin...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2014-11-01
|
Series: | International Journal of Infectious Diseases |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971214015689 |
id |
doaj-284fe328e1174932806b04908c6350dc |
---|---|
record_format |
Article |
spelling |
doaj-284fe328e1174932806b04908c6350dc2020-11-25T00:18:26ZengElsevierInternational Journal of Infectious Diseases1201-97121878-35112014-11-0128C20421010.1016/j.ijid.2014.06.008Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adultsHoan Jong Lee0Moon-Hyun Chung1Woo Joo Kim2Young Jin Hong3Kyong Min Choi4Jina Lee5Chi Eun Oh6Jo Anne Welsch7Kyung-Hyo Kim8Ki Bae Hong9Alemnew F. Dagnew10Hans Bock11Peter M. Dull12Tatjana Odrljin13Seoul National University Children's Hospital, 101 Daehak-ro, Jongno-gu, Seoul 110-769, KoreaInha University Hospital, Incheon, KoreaKorea University Guro Hospital, Seoul, KoreaInha University Hospital, Incheon, KoreaMyongji Hospital, Kwandong University College of Medicine, Koyang, KoreaSeoul National University Bundang Hospital, Seongnam, KoreaKosin University College of Medicine, Busan, KoreaNovartis Vaccines and Diagnostics, Cambridge, Massachusetts, USAEwha Womans University School of Medicine, Seoul, KoreaSeoul National University Children's Hospital, 101 Daehak-ro, Jongno-gu, Seoul 110-769, KoreaNovartis Vaccines and Diagnostics, Cambridge, Massachusetts, USANovartis Vaccines and Diagnostics, Cambridge, Massachusetts, USANovartis Vaccines and Diagnostics, Cambridge, Massachusetts, USANovartis Vaccines and Diagnostics, Cambridge, Massachusetts, USA Objectives: This phase III placebo-controlled study evaluated the immunogenicity and safety of MenACWY-CRM vaccination in healthy Korean adolescents and adults. Methods: Serum bactericidal activity with human complement (hSBA) was measured before and 1 month after vaccination against all four meningococcal serogroups. The IgG concentration specific for serogroup W capsular polysaccharide was measured in a subset of subjects in a post-hoc analysis. Adverse reactions were monitored throughout the study. Results: Four hundred and fifty subjects were randomized 2:1 to receive MenACWY-CRM (N = 297) or a saline placebo (N = 153). MenACWY-CRM induced a good immune response against all four serogroups, with seroprotection rates (hSBA titers ≥8) of 79%, 99%, 98%, and 94% for serogroups A, C, W, and Y, respectively. Seroresponse rates were high for serogroups A, C, and Y, i.e. 76%, 86%, and 69%, respectively; the rate for serogroup W was 28%. MenACWY-CRM vaccine induced serum bactericidal antibodies against all four serogroups in a majority of subjects regardless of their baseline hSBA titers. MenACWY-CRM was generally well tolerated with most reactions being transient and mild to moderate in severity. Conclusions: Findings of this first study of a quadrivalent meningococcal polysaccharide conjugate vaccine in Korean adults and adolescents demonstrated that a single dose of MenACWY-CRM was well tolerated and immunogenic, as indicated by the percentages of subjects with hSBA titers ≥8 (79%, 99%, 98%, and 94% of subjects) and geometric mean titers (48, 231, 147, and 107) against serogroups A, C, W, and Y, respectively, at 1 month post-vaccination. http://www.sciencedirect.com/science/article/pii/S1201971214015689Neisseria meningitidisConjugate vaccinesQuadrivalent meningococcal vaccineKorea |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hoan Jong Lee Moon-Hyun Chung Woo Joo Kim Young Jin Hong Kyong Min Choi Jina Lee Chi Eun Oh Jo Anne Welsch Kyung-Hyo Kim Ki Bae Hong Alemnew F. Dagnew Hans Bock Peter M. Dull Tatjana Odrljin |
spellingShingle |
Hoan Jong Lee Moon-Hyun Chung Woo Joo Kim Young Jin Hong Kyong Min Choi Jina Lee Chi Eun Oh Jo Anne Welsch Kyung-Hyo Kim Ki Bae Hong Alemnew F. Dagnew Hans Bock Peter M. Dull Tatjana Odrljin Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adults International Journal of Infectious Diseases Neisseria meningitidis Conjugate vaccines Quadrivalent meningococcal vaccine Korea |
author_facet |
Hoan Jong Lee Moon-Hyun Chung Woo Joo Kim Young Jin Hong Kyong Min Choi Jina Lee Chi Eun Oh Jo Anne Welsch Kyung-Hyo Kim Ki Bae Hong Alemnew F. Dagnew Hans Bock Peter M. Dull Tatjana Odrljin |
author_sort |
Hoan Jong Lee |
title |
Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adults |
title_short |
Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adults |
title_full |
Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adults |
title_fullStr |
Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adults |
title_full_unstemmed |
Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adults |
title_sort |
immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (menacwy-crm) in healthy korean adolescents and adults |
publisher |
Elsevier |
series |
International Journal of Infectious Diseases |
issn |
1201-9712 1878-3511 |
publishDate |
2014-11-01 |
description |
Objectives: This phase III placebo-controlled study evaluated the immunogenicity and safety of MenACWY-CRM vaccination in healthy Korean adolescents and adults.
Methods: Serum bactericidal activity with human complement (hSBA) was measured before and 1 month after vaccination against all four meningococcal serogroups. The IgG concentration specific for serogroup W capsular polysaccharide was measured in a subset of subjects in a post-hoc analysis. Adverse reactions were monitored throughout the study.
Results: Four hundred and fifty subjects were randomized 2:1 to receive MenACWY-CRM (N = 297) or a saline placebo (N = 153). MenACWY-CRM induced a good immune response against all four serogroups, with seroprotection rates (hSBA titers ≥8) of 79%, 99%, 98%, and 94% for serogroups A, C, W, and Y, respectively. Seroresponse rates were high for serogroups A, C, and Y, i.e. 76%, 86%, and 69%, respectively; the rate for serogroup W was 28%. MenACWY-CRM vaccine induced serum bactericidal antibodies against all four serogroups in a majority of subjects regardless of their baseline hSBA titers. MenACWY-CRM was generally well tolerated with most reactions being transient and mild to moderate in severity.
Conclusions: Findings of this first study of a quadrivalent meningococcal polysaccharide conjugate vaccine in Korean adults and adolescents demonstrated that a single dose of MenACWY-CRM was well tolerated and immunogenic, as indicated by the percentages of subjects with hSBA titers ≥8 (79%, 99%, 98%, and 94% of subjects) and geometric mean titers (48, 231, 147, and 107) against serogroups A, C, W, and Y, respectively, at 1 month post-vaccination.
|
topic |
Neisseria meningitidis Conjugate vaccines Quadrivalent meningococcal vaccine Korea |
url |
http://www.sciencedirect.com/science/article/pii/S1201971214015689 |
work_keys_str_mv |
AT hoanjonglee immunogenicityandsafetyofanovelquadrivalentmeningococcalconjugatevaccinemenacwycrminhealthykoreanadolescentsandadults AT moonhyunchung immunogenicityandsafetyofanovelquadrivalentmeningococcalconjugatevaccinemenacwycrminhealthykoreanadolescentsandadults AT woojookim immunogenicityandsafetyofanovelquadrivalentmeningococcalconjugatevaccinemenacwycrminhealthykoreanadolescentsandadults AT youngjinhong immunogenicityandsafetyofanovelquadrivalentmeningococcalconjugatevaccinemenacwycrminhealthykoreanadolescentsandadults AT kyongminchoi immunogenicityandsafetyofanovelquadrivalentmeningococcalconjugatevaccinemenacwycrminhealthykoreanadolescentsandadults AT jinalee immunogenicityandsafetyofanovelquadrivalentmeningococcalconjugatevaccinemenacwycrminhealthykoreanadolescentsandadults AT chieunoh immunogenicityandsafetyofanovelquadrivalentmeningococcalconjugatevaccinemenacwycrminhealthykoreanadolescentsandadults AT joannewelsch immunogenicityandsafetyofanovelquadrivalentmeningococcalconjugatevaccinemenacwycrminhealthykoreanadolescentsandadults AT kyunghyokim immunogenicityandsafetyofanovelquadrivalentmeningococcalconjugatevaccinemenacwycrminhealthykoreanadolescentsandadults AT kibaehong immunogenicityandsafetyofanovelquadrivalentmeningococcalconjugatevaccinemenacwycrminhealthykoreanadolescentsandadults AT alemnewfdagnew immunogenicityandsafetyofanovelquadrivalentmeningococcalconjugatevaccinemenacwycrminhealthykoreanadolescentsandadults AT hansbock immunogenicityandsafetyofanovelquadrivalentmeningococcalconjugatevaccinemenacwycrminhealthykoreanadolescentsandadults AT petermdull immunogenicityandsafetyofanovelquadrivalentmeningococcalconjugatevaccinemenacwycrminhealthykoreanadolescentsandadults AT tatjanaodrljin immunogenicityandsafetyofanovelquadrivalentmeningococcalconjugatevaccinemenacwycrminhealthykoreanadolescentsandadults |
_version_ |
1725376538952597504 |